A cost-effectiveness analysis of escitalopram and sertraline in the treatment of major depressive disorder

被引：2

作者：

Armstrong, EP

Skrepnek, GH

Malone, DC

Erder, H

机构：

[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA

[2] Forest Res Inst, Jersey City, NJ USA

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)63063-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：393 / 393

页数：1

共 50 条

[21] A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the United Kingdom
Hemels, ME
Toumi, I
Wade, AG
[J]. VALUE IN HEALTH, 2004, 7 (06) : 778 - 778
[22] Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
Groessl, Erik J.
Tally, Steven R.
Hillery, Naomi
Maciel, Alejandra
Garces, Jorge A.
[J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (08): : 726 - 734
[23] Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
Kulp W.
Graf Von Der Schulenburg J.-M.
Greiner W.
[J]. The European Journal of Health Economics, 2005, 6 (4) : 317 - 321
[24] Probabilistic cost-effectiveness model of escitalopram compared with citalopram and venlafaxine in primary care treatment of major depressive disorder in Denmark.
Hemels, MEH
Sorensen, J
Stage, KB
Damsbo, N
LeLay, A
[J]. NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 412 - 412
[25] A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder
Armstrong, Edward P.
Malone, Daniel C.
Erder, M. Haim
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (04) : 1115 - 1121
[26] Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder
Fernandez, JL
Montgomery, S
Francois, C
[J]. PHARMACOECONOMICS, 2005, 23 (02) : 155 - 167
[27] Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder
José-Luis Fernandez
Stuart Montgomery
Clément Francois
[J]. PharmacoEconomics, 2005, 23 : 155 - 167
[28] Escitalopram in major depressive disorder:: clinical benefits and cost effectiveness versus citalopram
Lancon, Christophe
Verpillat, Patrice
Annemans, Lieven
Despiegel, Nicolas
Francois, Clement
[J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 (01) : 44 - 52
[29] Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder
Nordstrom, Goran
Danchenko, Natalya
Despiegel, Nicolas
Marteau, Florence
[J]. VALUE IN HEALTH, 2012, 15 (02) : 231 - 239
[30] Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation
Llorca, P. M.
Fernandez, J. -L.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (04) : 702 - 710

← 1 2 3 4 5 →